

# Increased frequency of *ESR1* mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor

KAORU TAKESHIMA<sup>1</sup>, TETSU HAYASHIDA<sup>2</sup>, HINAKO MAEDA<sup>2</sup>, AYAKO NAKASHOJI<sup>2</sup>, TAKAMICHI YOKOE<sup>2</sup>, TOMOKO SEKI<sup>2</sup>, MAIKO TAKAHASHI<sup>2</sup> and YUKO KITAGAWA<sup>2</sup>

<sup>1</sup>Department of Surgery, Saitama City Hospital, Saitama 336-0911;

<sup>2</sup>Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan

Received December 25, 2019; Accepted April 30, 2020

DOI: 10.3892/ol.2020.11669

**Abstract.** In several recent studies on metastatic breast cancer (MBC), ligand binding domain mutations of the estrogen receptor, which is coded by the *ESR1* gene, were induced by long-term endocrine therapy and resulted in acquired endocrine therapy resistance and poor outcomes. Knowledge of the association between the development of *ESR1* mutation and the clinicopathologic features may guide the decision-making process of metastatic breast cancer treatment, including endocrine therapy. The aim of the present study was to evaluate the association between the development of *ESR1* mutation and the clinicopathologic characteristics of patients with MBC. To evaluate the association between the development of *ESR1* mutation and clinicopathologic features, a cohort of 22 patients with MBC were retrospectively analyzed using next generation sequencing. In 14 of 22 patients, four mutations were detected on the metastatic site, including Tyr537Ser, Glu542Asp, Leu536Arg and Arg548Cys. Univariate analysis demonstrated that the duration of aromatase inhibitor and selective estrogen receptor modulator treatment, as well as the age of treatment initiation for early-stage breast cancer, were significantly associated with the development of *ESR1* mutation. *ESR1* mutation was identified in all five patients who

received selective estrogen receptor modulators in the adjuvant setting followed by aromatase inhibitors in the metastatic setting, as well as in two of the three patients who received no selective estrogen receptor modulators in adjuvant setting followed by aromatase inhibitors in the metastatic setting. In conclusion, the results of the present study suggested that administering adjuvant selective estrogen receptor modulator followed by aromatase inhibitor for metastasis may increase the frequency of *ESR1* mutation.

## Introduction

Estrogen receptor (ER), which is encoded in the estrogen receptor 1 (*ESR1*) gene, belongs to the nuclear hormone receptor family (1) and the *ESR1* gene is located on chromosome 6 (6q25.1) and includes 8 exons (2). ER is expressed in over 60% of breast cancers (3) and consists of two activation function domains, AF1/2, a DNA binding domain and a hinge domain, and a ligand-binding domain (LBD) (4). ER functions as a ligand-dependent transcription factor, and ligand binding to the LBD leads to activation of gene transcription, resulting in breast cancer progression (5,6). Adjuvant endocrine therapy (ET) inhibiting ER-induced breast cancer progression reduces local recurrence and mortality in patients with ER-positive early breast cancer (3,7). Similarly, ET with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and selective estrogen receptor degrader (SERD) serves an important role in the treatment of patients with ER-positive metastatic breast cancer (MBC) (1). However, a number of patients with ER-positive MBC have intrinsic ET resistance or acquire resistance following response to ET, and eventually almost all patients with MBC develop resistance to ET (8). ET resistance mechanisms include upregulation of the steroid receptor coactivator-3, human epidermal growth factor 2 (HER2) or nuclear factor  $\kappa$ B and activator protein 1 (9-11). Cyclin D1 gene amplification frequently occurs in ER-positive breast cancer and overexpression of Cyclin D1 leads to ET resistance in ER-positive breast cancer (12,13). A number of previous studies indicated that LBD mutations (i.e., Tyr537Ser and Asp538Gly) in *ESR1* gene were induced by long-term ET and resulted in acquired ET resistance independently of

---

*Correspondence to:* Dr Tetsu Hayashida, Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan  
E-mail: tetsu@keio.jp

**Abbreviations:** AI, aromatase inhibitor; ER, estrogen receptor; ET, endocrine therapy; LBD, ligand-binding domain; MBC, metastatic breast cancer; NGS, next generation sequencing; OS, overall survival; PFS, progression-free survival; PgR, progesterone receptor; SERD, selective estrogen receptor degrader; SERM, selective estrogen receptor modulator

**Key words:** aromatase inhibitor, endocrine therapy resistance, *ESR1* mutation, metastatic breast cancer, selective estrogen receptor modulator

estrogen levels, as well as poor outcomes in patients with MBC (14–18). Knowledge of the associations between the development of *ESR1* mutation and patient clinicopathological characteristics may guide the decision-making process of MBC treatment, including ET. The aim of the present study was to evaluate the association between the development of *ESR1* mutation and the clinicopathologic characteristics of patients with MBC.

## Materials and methods

**Clinical samples.** Patients with MBC who had received treatment for primary ER-positive breast cancer and were followed-up at Keio University Hospital between January 2012 and December 2015 were enrolled in this study; during that period, 24 biopsy samples from the metastatic sites were available for analysis. The inclusion and exclusion criteria were as follows: Metastatic samples with  $\geq 100\times$  sequence coverage on next generation sequence (NGS) were included, while samples  $< 100\times$  sequence coverage were excluded from the present study. Metastatic samples were evaluated by NGS, with a level of sequence coverage of  $> 100$ -fold, to detect the LBD mutations of the *ESR1* gene and validate these ER mutations in patients with MBC. The 24 metastatic site samples were assessed, and two were excluded from NGS due to low sequence coverage. Thus, a total of 22 metastatic samples were evaluated in the present study. The Allred score was used to assess the receptor status at metastatic sites (19). The clinical data, including the ET administered and clinical outcomes, were obtained from all patients. The study protocol and the opt-out informed consent procedure were approved by the Ethics Review Board of Keio University Hospital and conformed to the Declaration of Helsinki. Informed consent was acquired from the patients by opt-out procedure prior to the beginning of the study.

**DNA extraction.** Using the biopsy samples from the MBC patients, unstained 10- $\mu\text{m}$  thick formalin-fixed paraffin embedded (FFPE) blocks were obtained. Tumor tissue was collected from the two blocks and placed in 1.5 ml microtubes. Genomic DNA was extracted using a NucleoSpin DNA FFPE XS isolation kit (Takara Bio, Inc.). DNA was quantified by Qubit 3.0 Fluorometer using the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions, and adjusted to a final concentration of 20 ng/ $\mu\text{l}$ .

**Target amplification and sequencing.** For target amplification of the mutation hotspot in the LBD of the *ESR1* gene, PCR of the extracted genomic DNA was performed using custom primers and ligating Illumina read1 and read2 sequences (Illumina, Inc.). The second PCR primer pairs were used to ligate the Illumina adaptor and index sequence to the first PCR products. The target amplification PCR primer sequences were as follows: Forward, 5'-ACACTCTTCCCTACACGACGCTCTCCGATCTGGCTCGGGTTGGCTCTAAA-3' and reverse, 5'-GTGACTGGAGTTCAGACGTGTGCTCTCCGATCTTAGTGGGCGCATGTAGGC-3'. The second PCR primer sequences were as follows: Forward, 5'-AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACAGACGCTCTCCGATCT-3' and reverse, 5'-CAAGCA


GAAGACGGCATAACGAGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3' (NNNNNN: Index sequence). These sequences refer to *ESR1*. Fig. 1 demonstrates the target amplification PCR primer pairs and the second PCR primer pairs. In a 10- $\mu\text{l}$  reaction buffer that contained 5 mM deoxynucleotide triphosphate mix, 0.25  $\mu\text{M}$  of each custom made primer and 0.2  $\mu\text{l}$  Herculase II Fusion DNA polymerase (Agilent Technologies, Inc.), 20 ng of the genomic DNA underwent amplification for 20 cycles of 10 sec at 98°C, 30 sec at 55°C and 30 sec at 72°C. The amplicon, which was 1  $\mu\text{l}$  of the PCR product diluted 10 times, was marked in a second PCR with molecular indices for Illumina Miseq, using TrueSeq DNA HT Sample Kits (Illumina, Inc.). The second amplification was performed as aforementioned.

DNA libraries were formed from the second PCR products, which were purified using the Agencourt AMPure XP reagent, according to the manufacturer's instructions (Beckman Coulter, Inc.) and quantified by the method described above. The library was sequenced on the Miseq instrument on the paired-end mode with the Miseq Reagent kit v3 (Illumina, Inc.) according to the manufacturer's instructions. The sequence data were mapped to the reference human genome (*hg19*) using BWA aligner [version 0.7.16a-r1181; (20)], SAMtools [version 1.6; (21)] and Picard (<http://sourceforge.net/projects/picard>). Local alignment and quality score calibration were performed according to the Genome Analysis Toolkit (GATK) best practice (22). Single nucleotide variants were called using the 'HaplotypeCaller' tool in GATK. All variants were annotated using snpEff (23) and reviewed by the Integrative Genomics Viewer (24). Variants were filtered using dbSNP\_138 (<http://www.ncbi.nlm.nih.gov/projects/SNP>). GRCh37.75 in the Ensembl genome browser (<http://www.ensembl.org>) was used as the reference genome of annotation.

**Statistical analysis.** Statistical analyses were performed with R commander (version 2.4-1) based on R (version 3.3.3; <http://cran.r-project.org/>) and with EZR, which is a modified version of the R commander (25). Among the continuous variables, age followed a normal distribution as determined by the Shapiro-Wilk test; thus, it was presented as the mean  $\pm$  standard deviation and analyzed using the independent two-sample Student's t-test. The other continuous variables were expressed as the median (range) and evaluated by the Wilcoxon rank sum test. Categorical variables were analyzed by the Fisher's exact test. The correlation between two continuous variables was evaluated by calculating Spearman's rank correlation coefficient.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**Baseline characteristics and detection of *ESR1* mutations in patients with MBC.** The baseline characteristics of the 22 patients with MBC are presented in Table I. The mean age of the patients at the start of treatment was 54 years. The TNM stage of primary breast cancer was I in 7 (32%) patients, IIA in 9 (41%) patients, IIB in 4 (18) patients, IIIB in 1 (5%) patient and IV in 1 (5%) patient. The histologic type of primary lesion was invasive ductal carcinoma in 21 (95%) patients and invasive lobular carcinoma in 1 (5%) patient. The Progesterone receptor



Target amplification PCR primer

P1: 5'-ACACTCTTCCCTACACGACGCTCTTCCGATCTGGCTCGGGTTGGCTCTAAA-3'

P2: 5'-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTAGTGGGCGCATGTAGGC-3'

Second PCR primer

5'-AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTTCCGATCT-3'

5'-CAAGCAGAAGACGGCATAACGAGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCC  
GATCT-3'

NNNNNN :Index sequence

Figure 1. The primer sequences used for target amplification.

(PgR) and HER2 status of the primary tumor was positive in 21 (95%) and four (18%) patients, respectively; HER2 status was unknown in one case.

As presented in Table II, *ESR1* mutation at the metastatic site was observed in 14 (64%) of the 22 patients. A total of four *ESR1* mutations were identified including 1610A>C, 1626G>T, 1607T>G and 1642C>T, which led to amino acid mutations Tyr537Ser in 10 (45%) patients, Glu542Asp in 2 (9%) patients, Leu536Arg in 1 (5%) patient and Arg548Cys in 1 (5%) patient, respectively. The range of allele mutation frequency was 2-99%.

*ESR1* mutation and the clinical characteristics of patients with MBC. The ER Allred score of the primary tumor was positive by immunohistochemical staining in all 22 patients prior to this study (19). Of the 22 samples, 21 and 17 were positive for ER and PgR, respectively (unavailable in 1 sample). The metastatic biopsy site was the liver in 7 (32%) patients, skin in 6 (27%) patients, lymph node in 4 (18%) patients, lung in 3 (14%) patients, bone in 1 (5%) patient and muscle in 1 (5%) patient.

Among the 22 patients with MBC, including one with stage IV cancer, 19 patients received at least one ET agent

Table I. The baseline characteristics of 22 patients with metastatic breast cancer.

Variable	Number of patients (%)
Age at the start of treatment, years	54±13
TNM stage of primary breast cancer	
I	7 (32)
IIA	9 (41)
IIB	4 (18)
IIIA	0 (0)
IIIB	1 (5)
IIIC	0 (0)
IV	1 (5)
Histological type	
Invasive ductal	21 (95)
Invasive lobular	1 (5)
PgR status of the primary tumor	
Positive	21 (95)
Negative	1 (5)
HER2 status of the primary tumor	
Positive	4 (18)
Negative	17 (77)
Unknown	1 (5)

TNM, Tumor-Node-Metastasis; PgR, progesterone receptor.

prior to the metastatic site biopsy; *ESR1* mutation was detected in 13 patients, but it was not detected in 6 patients. Of the 21 patients with MBC (excluding the patient with stage IV MBC), 16 patients received ET in an adjuvant setting, which was complete in 10 cases and incomplete in 6 cases. An incomplete adjuvant setting was defined as recurrence of breast cancer within five years of treatment. Among the 16 patients who received ET in the adjuvant setting, *ESR1* mutation was detected in 2 of 6 patients who received AIs, in 8 of 9 patients who received SERMs and in 1 patient who received both AI and SERM. Between the recurrence and the biopsy of the metastatic site, 7 of 8 patients who received AIs developed *ESR1* mutation. *ESR1* mutation was identified in all 5 patients who received SERM in the adjuvant setting followed by AI in the metastatic setting, as well as in 2 of 3 patients who did not receive SERM in adjuvant setting followed by AI in the metastatic setting. In addition, 7 of 8 patients who had no *ESR1* mutation did not receive any ET for metastasis. The patient with stage IV MBC, who was administered AIs until the biopsy of the metastatic site, developed *ESR1* mutation. These results are presented in Table III.

*Association between ESR1 mutation and clinicopathological characteristics in 22 patients with MBC.* Considering the total period between the beginning of treatment and the biopsy of the metastatic site in 22 patients with MBC, the SERM intake period was significantly longer in patients with *ESR1* mutation compared with that in patients with wild-type *ESR1* (26 vs. 0 months;  $P=0.01$ ). The total interval of treatment with AI and

Table II. Cases of metastatic breast cancer with estrogen receptor 1 mutations (n=14).

Case no.	Mutation	Amino acid change	Mutation frequency, %
1	1610A>C	Tyr537Ser	96
2	1610A>C	Tyr537Ser	99
3	1610A>C	Tyr537Ser	79
4	1610A>C	Tyr537Ser	15
5	1610A>C	Tyr537Ser	87
6	1610A>C	Tyr537Ser	22
7	1610A>C	Tyr537Ser	36
8	1642C>T	Arg548Cys	2
9	1610A>C	Tyr537Ser	18
10	1610A>C	Tyr537Ser	58
11	1610A>C	Tyr537Ser	21
12	1607T>G	Leu536Arg	68
13	1626G>T	Glu542Asp	15
14	1626G>T	Glu542Asp	20

AI/ SERM was not significantly different between patients with *ESR1* mutation and those without *ESR1* mutation ( $P=0.92$  and  $P=0.13$ , respectively; Table IV).

Considering the treatment period from recurrence to biopsy of the metastatic site in 21 patients with MBC, after excluding the stage IV case, the AI intake period was significantly longer in patients with *ESR1* mutation than in those without *ESR1* mutation (5 vs. 0 months;  $P=0.04$ ; Table IV). However, there were no significant differences in the treatment period with SERM or AI/ SERM between patients with and without *ESR1* mutation ( $P=0.83$  and  $P=0.05$ , respectively).

The age at the time of treatment initiation was significantly lower in patients with mutant *ESR1* compared with that in patients without mutant *ESR1* ( $49\pm 11$  vs.  $63\pm 12$  years;  $P=0.01$ ; Table IV). There were no significant differences in the primary TNM stage, histologic type, PgR and HER2 status of primary tumor between the two patient groups. The number of administered ETs tended to be higher in patients with *ESR1* mutation compared with that in those without *ESR1* mutation, but the difference was not significant (1.5 vs. 0, respectively;  $P=0.06$ ; Table IV). The number of ETs administered to the patients from recurrence to biopsy was not significantly different between the two patient groups (1 vs. 0;  $P=0.10$ ). The age at the time of the initiating treatment was associated with the SERM intake period (Spearman's rank correlation coefficient,  $-0.45$ ;  $P=0.03$ ; Table IV).

## Discussion

In the present study on a cohort of patients with MBC, the presence of LBD mutations in the *ESR1* gene was detected by targeted NGS, and its association with patient clinicopathologic characteristics was assessed. The frequency of *ESR1* mutations in metastatic samples was 64% in this study and varied between 13 and 55% among published studies that also used NGS (14-16,26). Compared with previous studies,

Table III. *ESR1* mutations and the clinical data of 22 patients with metastatic breast cancer.

Case no.	Age, years <sup>a</sup>	Mutations	Allred of E/P <sup>b</sup>	Biopsy site	Adjuvant ET (months, status)	ET after recurrence to biopsy
1	74	Yes	7/0	Skin	AI (21, incomplete)	None
2	48	Yes	8/8	Liver	SERM (60, complete)	AI, SERD, AI
3	51	Yes	7/7	Skin	AI (7), SERM (53, complete)	None
4	35	Yes	8/8	LN	None	None
5	30	Yes	7/5	LN	None	AI, SERM, AI, SERD
6	56	Yes	Unavailable	Bone	AI (60, complete)	AI
7	54	Yes	8/7	Skin	SERM (60, complete)	None
8	47	Yes	7/0	Liver	SERM (22, incomplete)	AI, SERD
9	54	Yes	8/6	Skin	SERM (60, complete)	AI
10	39	Yes	8/8	Liver	SERM (24, incomplete)	AI, AI
11	51	Yes	8/8	Liver	SERM (24, complete)	None
12	57	Yes	8/7	Liver	SERM (60, complete)	AI
13	42	Yes	8/5	Skin	SERM (37, incomplete)	None
14	46	Yes	8/8	Liver	None	AI, AI
15	74	No	8/8	Skin	AI (60, complete)	None
16	75	No	8/8	Muscle	None	None
17	58	No	8/6	LN	AI (60, complete)	None
18	39	No	8/0	LN	SERM (23, incomplete)	None
19	59	No	8/8	Lung	None	AI, SERM
20	63	No	7/7	Lung	AI (58, incomplete)	None
21	60	No	8/0	Liver	AI (60, complete)	None
22	74	No	8/5	Lung	None	None

<sup>a</sup>Age at the start of treatment. <sup>b</sup>Allred score of E/P at metastasis. <sup>c</sup>The patient had stage IV breast cancer. Incomplete adjuvant setting is defined as the recurrence of breast cancer during adjuvant treatment. E/P, estrogen receptor/progesterone receptor; *ESR1*, estrogen receptor 1; ET, endocrine treatment; AI, aromatase inhibitor; SERM, selective estrogen receptor modulator; SERD, selective estrogen receptor degrader; LN, lymph node; PgR, progesterone receptor.

the present study had a higher frequency of *ESR1* mutations and a lower number of administered ETs. This study demonstrated that there was no association between the number of administered ET and the development of *ESR1* mutation. Two previous studies have demonstrated an association between ET exposure and the prevalence of mutated *ESR1* (26,27), although the number of previously administered ET was not clarified.

In the current study, the *ESR1* mutations Leu536Arg, Tyr537Ser, Glu542Asp and Arg548Cys were detected. The Tyr537Ser and Arg548Cys mutations have been demonstrated to induce estrogen-independent activity of the ER, leading to ET resistance (15,28). In addition, bioinformatics analysis has indicated that an Arg548Cys mutation in the ER is deleterious (29). Similarly, amino acid mutations in Leu536 have been reported to increase the estrogen-independent activity of the ER (30), and Toy *et al* (15) identified the Leu536Arg mutation in the ER, but they did not investigate its function. The impact of the Glu542Asp alteration on the ER function remains unknown and further investigation is needed (31). Therefore, the detected ER mutations in this study, with the exception of Glu542Asp, may induce a ligand-independent ER activation resulting in ET resistance. It is important to deter-

mine the changes of *ESR1* alterations between primary and metastatic tumor; however, in this study, the *ESR1* mutations of the primary lesion were not investigated because primary breast cancers have very rare *ESR1* mutation, which has been reported in previous studies, including The Cancer Atlas data (32-34).

A number of previous studies on patients with MBC have demonstrated that compared with wild-type *ESR1*, *ESR1* mutation led to worse progression-free survival (PFS) and overall survival (OS) (35,36). However, in the present study, *ESR1* mutation had no adverse impact on the outcomes of patients with MBC (data not shown). The small cohort used in the present study limited the statistical power to assess the impact on the outcomes of patients with MBC.

This may be due to the Glu542Asp mutation, which was detected in 2 patients with MBC in this study, having no negative effect on the patients' outcomes. The present study revealed that prolonged AI treatment for metastasis had a significant impact on the development of *ESR1* mutation and that patients with MBC who received AIs in an adjuvant setting exhibited low rates of *ESR1* mutation. A number of previous studies reported that mutated *ESR1* rarely occurred during adjuvant therapy with AI, but its prevalence was high

Table IV. Association between estrogen receptor 1 gene mutation and clinicopathologic data in 22 patients with metastatic breast cancer.

A, According to the total duration from the beginning of treatment to biopsy of the metastatic site (n=22)			
Variable	Mutation (+)	Mutation (-)	P-value
AI	15 (0-83)	31 (0-60)	0.92
SERM	26 (0-60)	0 (0-23)	0.01
AI + SERM	60 (0-143)	41 (0-60)	0.13
B, According to the total duration from recurrence to biopsy of the metastatic site (n=21)			
Variable	Mutation (+)	Mutation (-)	P-value
AI	5 (0-83)	0 (0-3)	0.04
SERM	0 (0-27)	0 (0-7)	0.83
AI + SERM	5 (0-83)	0 (0-10)	0.05
C, According to clinicopathological characteristics (n=22)			
Variable	Mutation (+)	Mutation (-)	P-value
Age at the start of treatment, years	49±11	63±12	0.01
Primary TNM stage			
I	4	3	
IIA	5	4	
IIB	3	1	
IIIA	0	0	
IIIB	1	0	
IIIC	0	0	
IV	1	0	
Histological type			
Invasive ductal	13	8	
Invasive lobular	1	0	>0.99
PgR status of the primary tumor			
Positive	13	8	
Negative	1	0	>0.99
HER2 status of the primary tumor			
Positive	2	2	
Negative	11	6	0.62
Total number of administered ET <sup>a</sup>	1.5 (0-3)	1 (0-1)	0.06
The number of ET from recurrence to biopsy	1 (0-3)	0 (0-2)	0.10
Spearman's rank correlation		Coefficient	
Age at the start of treatment vs. The total duration of SERM until biopsy of the metastatic site		-0.45	0.03

<sup>a</sup>Excluding SERD regimen. Values are expressed as the median (range) or the mean ± standard deviation and analyzed by Wilcoxon rank sum test, independent samples Student's t-test or Fisher's exact test. AI, aromatase inhibitor; SERM, selective estrogen receptor modulator; TNM, Tumor-Node-Metastasis; PgR, progesterone receptor; ET, endocrine treatment.

during recurrence treatment with AI (17,35). The results of the present study appeared to support these studies. Previous studies have also demonstrated the superior effects of

fulvestrant on the PFS and OS compared with those of anastrozole in patients with endocrine-sensitive MBC (37,38). Furthermore, the addition of palbociclib, a CDK4/6 inhibitor,

to letrozole or fulvestrant improved the PFS in patients with MBC (39,40). Of note, it was reported that palbociclib combined with fulvestrant improved the PFS irrespective of the *ESR1* mutation status in patients with MBC (41) and that palbociclib plus letrozole did not prevent the development of *ESR1* mutation in a small cohort of patients with MBC who received the combination treatment (42). These results suggest that the assessment of dynamic changes of the *ESR1* mutation status using minimally invasive procedures such as liquid biopsy in patients with MBC who receive CDK4/6 inhibitors may be of importance for investigating acquired resistance to these drugs.

The results of the present study demonstrated that the total period of SERM treatment was associated with the emergence of *ESR1* mutation. To the best of our knowledge, the effects of SERM on *ESR1* mutation have not been fully clarified to date. Among patients with MBC who received tamoxifen alone, *ESR1* mutation was not detected in all 22 patients in a study by Schiavon *et al* (17), but it was detected in 4 out of 11 patients in a study by Takeshita *et al* (43). The present study demonstrated that the frequency rate of *ESR1* alteration in patients who received adjuvant-SERM followed by metastatic AI treatment was higher compared with that in patients who received no adjuvant-SERM followed by metastatic AI. The association of SERM with *ESR1* mutation that was identified in this study may be explained by the finding that most of the patients with mutated *ESR1* who received AIs for metastasis had been administered SERMs in an adjuvant setting. Administration of SERM in an adjuvant setting may have been used as a compelling indication for the use of AI for metastasis; therefore, SERM for adjuvant setting, followed by AI for metastasis, may increase the frequency of *ESR1* mutations. However, this result needs to be clarified and verified in a future study.

The present study revealed that age at the time of treatment initiation for breast cancer was significantly associated with the development of *ESR1* mutation and the total duration of SERM treatment. These associations may be due to the premenopausal status of the majority of patients with MBC who received SERM in an adjuvant setting and AI in a metastatic setting, leading to the subsequent development of *ESR1* mutation. To the best of our knowledge, no previous studies have demonstrated an association between age at the time of treatment initiation for breast cancer and the occurrence of *ESR1* gene mutation.

This study had several limitations, including the retrospective design using a small cohort from a single institute. In addition, the effects of SERD on *ESR1* mutations were not analyzed, as only three patients with MBC received SERD, and no multivariate analysis was performed due to the small cohort. The small cohort of this study limited the statistical power to assess the association between *ESR1* mutation and clinicopathological features in patients with MBC.

In conclusion, the results of the present study demonstrated that SERM in an adjuvant setting followed by AI for metastasis may increase the frequency of *ESR1* mutation, and that age at the time of treatment onset for breast cancer may be significantly associated with the development of *ESR1* mutation. Further studies are needed to confirm and validate these findings.

## Acknowledgements

The authors would like to thank Mr. Kazuhiro Miyao at the Department of Surgery, Keio University School of Medicine (Tokyo, Japan) for his excellent technical assistance and helpful insights on DNA extraction and next generation sequencing.

## Funding

The present study was supported by a grant-in-aid from the Japan Society for the Promotion Science (grant no. 16K10474 to MT).

## Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

## Authors' contributions

KT, TH, TS, MT and YK conceived and designed this study. HM, AN and TY performed the experiments and collected clinical data from the patients. KT analyzed data and drafted the manuscript. All authors revised the manuscript and approved the final version.

## Ethics approval and consent to participate

The study protocol, including the opt-out informed consent procedure, was approved by the Ethics Review Board of Keio University Hospital (approval no. 20150439) and conformed to Declaration of Helsinki.

## Patient consent for publication

Not applicable.

## Competing interests

TH and YK received lecture fee and research funding from Pfizer Inc., Novartis Pharma K.K., and AstraZeneca. All other authors confirm that they have no competing interests.

## References

- Olefsky JM: Nuclear receptor minireview series. *J Biol Chem* 276: 36863-36864, 2001.
- Gianluca A, Flavia P and Paolo M: Update on Mechanisms of Hormone Action: Focus on Metabolism, Growth and Reproduction. Tech, Rijeka, Croatia, pp71-73, 2011.
- Tamoxifen for early breast cancer: An overview of the randomised trials. *Early Breast Cancer Trialists' Collaborative Group. Lancet* 351: 1451-1467, 1998.
- Ruff M, Gangloff M, Wurtz JM and Moras D: Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. *Breast Cancer Res* 2: 353-359, 2000.
- Kojetin DJ, Burris TP, Jensen EV and Khan SA: Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. *Endocr Relat Cancer* 15: 851-870, 2008.
- Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M and Gustafsson JA: Estrogen receptors: How do they signal and what are their targets. *Physiol Rev* 87: 905-931, 2007.

7. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. *J Clin Oncol* 19: 3817-3827, 2001.
8. Pritchard KI: Endocrine therapy: Is the first generation of targeted drugs the last? *J Intern Med* 274: 144-152, 2013.
9. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM and Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. *J Natl Cancer Inst* 95: 353-361, 2003.
10. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK and Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. *Clin Cancer Res* 10 (Suppl): S331-S336, 2004.
11. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S and Benz CC: Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. *BMC Cancer* 7: 59, 2007.
12. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R and Knudsen ES: Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer. *Endocr Relat Cancer* 18: 333-345, 2011.
13. Witkiewicz AK and Knudsen ES: Retinoblastoma tumor suppressor pathway in breast cancer: Prognosis, precision medicine, and therapeutic interventions. *Breast Cancer Res* 16: 207, 2014.
14. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, *et al*: Activating *ESR1* mutations in hormone-resistant metastatic breast cancer. *Nat Genet* 45: 1446-1451, 2013.
15. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, *et al*: *ESR1* ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet* 45: 1439-1445, 2013.
16. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, *et al*: D538G mutation in estrogen receptor- $\alpha$ : A novel mechanism for acquired endocrine resistance in breast cancer. *Cancer Res* 73: 6856-6864, 2013.
17. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, *et al*: Analysis of *ESR1* mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. *Sci Transl Med* 7: 313ra182, 2015.
18. Reinert T, Saad ED, Barrios CH and Bines J: Clinical implications of *ESR1* mutations in hormone receptor-positive advanced breast cancer. *Front Oncol* 7: 26, 2017.
19. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol* 11: 155-168, 1998.
20. Li H and Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25: 1754-1760, 2009.
21. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25: 2078-2079, 2009.
22. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, *et al*: A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 43: 491-498, 2011.
23. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X and Ruden DM: A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 6: 80-92, 2012.
24. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G and Mesirov JP: Integrative genomics viewer. *Nat Biotechnol* 29: 24-26, 2011.
25. Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 48: 452-458, 2013.
26. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, *et al*: Emergence of constitutively active estrogen receptor- $\alpha$  mutations in pretreated advanced estrogen receptor-positive breast cancer. *Clin Cancer Res* 20: 1757-1767, 2014.
27. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y and Iwase H: Comparison of *ESR1* mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients. *Transl Oncol* 10: 766-771, 2017.
28. Li B, Liu L, Fu X, Zhou WQ, Zou DT, Zhao XY, Cai YN, Tu HB, Liu QC and Chen YY: A novel mutation of estrogen receptor gene detected in girls with precocious puberty. *Yi Chuan Xue Bao* 32: 1011-1017, 2005.
29. Rebai M and Rebai A: In silico characterization of functional SNP within the oestrogen receptor gene. *J Genet* 95: 865-874, 2016.
30. Zhao C, Koide A, Abrams J, Deighton-Collins S, Martinez A, Schwartz JA, Koide S and Skafar DF: Mutation of Leu-536 in human estrogen receptor- $\alpha$  alters the coupling between ligand binding, transcription activation, and receptor conformation. *J Biol Chem* 278: 27278-27286, 2003.
31. Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, *et al*: Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. *Ann Oncol* 28: 2866-2873, 2017.
32. Karnik PS, Kulkarni S, Liu XP, Budd GT and Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. *Cancer Res* 54: 349-353, 1994.
33. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD and Parl FF: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. *J Natl Cancer Inst* 87: 446-451, 1995.
34. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. *Nature* 490: 61-70, 2012.
35. Chandraratnam S, Chen D, He W, Sung P, Samoilu A, You D, Bhatt T, Patel P, Voi M, Gnant M, *et al*: Prevalence of *ESR1* mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial. *JAMA Oncol* 2: 1310-1315, 2016.
36. Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, Sefrioui D, Viailly PJ, Bubenheim M, Moldovan C, *et al*: Kinetics, prognostic and predictive values of *ESR1* circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. *Oncotarget* 7: 74448-74459, 2016.
37. Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, *et al*: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial. *Lancet* 388: 2997-3005, 2016.
38. Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasińska M, Hewson N, Rukazenkova Y and Robertson JF: Fulvestrant 500 mg versus anastrozole 1 mg for the First-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. *J Clin Oncol* 33: 3781-3787, 2015.
39. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, *et al*: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol* 16: 25-35, 2015.
40. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, *et al*: Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med* 373: 209-219, 2015.
41. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, *et al*: Plasma *ESR1* mutations and the treatment of estrogen receptor-positive advanced breast cancer. *J Clin Oncol* 34: 2961-2968, 2016.
42. Gyanchandani R, Kota KJ, Jonnalagadda AR, Minter T, Knapick BA, Oesterreich S, Brufsky AM, Lee AV and Puhalla SL: Detection of *ESR1* mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. *Oncotarget* 8: 66901-66911, 2016.
43. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y and Iwase H: Droplet digital polymerase chain reaction assay for screening of *ESR1* mutations in 325 breast cancer specimens. *Transl Res* 166: 540-553.e2, 2015.

